recent recommendations for approval from japan's cpac
Post on 09-Dec-2016
213 Views
Preview:
TRANSCRIPT
Inpharma 1254 - 9 Sep 2000
Recent recommendations forapproval from Japan’s CPAC
The Japanese Central Pharmaceutical Affairs Council(CPAC) has recently recommended a number ofproducts for approval, reports Scrip.
These products include:• protein C [‘Anact’; Kaketsuken] for the treatment of
disseminated intravascular coagulopathy andthrombosis caused by congenital protein Cdeficiency
• Schering AG’s interferon-β-1b [‘Betaferon’] for thetreatment of multiple sclerosis
• the hypnotic zolpidem [‘Myslee’; Sanofi-Synthelabo, Fujisawa] for the treatment of insomnia
• paroxetine [‘Paxil’; SmithKline Beecham] for thetreatment of depression and panic disorder
• Novartis’ angiotensin II receptor antagonistvalsartan [‘Diovan’] for the treatment ofhypertension
• fexofenadine [‘Allegra’; Aventis, Sepracor] for thetreatment of allergic rhinitis and urticaria
• ophthalmic acitazanolast [‘Zepelin’; Wakamoto,Kowa] for the treatment of allergic conjunctivitis.
Approval recommendations in Japan. Scrip : 20, No. 2569, 25 Aug2000 800839303
1
Inpharma 9 Sep 2000 No. 12541173-8324/10/1254-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
top related